LAMPIRE’s Llama vHH platform enables rapid discovery of single-domain antibodies (nanobodies) using proprietary single B cell sorting of antigen-positive llama and alpaca B cells. By combining camelid immunization expertise with advanced B cell technologies, we provide a streamlined path to highly specific and stable vHH binders for research, diagnostic, and therapeutic applications.

The sequence-forward vHH discovery approach delivers epitope-diverse nanobody candidates with strong biophysical properties while eliminating the bias of library-based methods. Multiple immunization sampling timepoints drive deeper affinity maturation, and direct sequence recovery ensures full transparency and client ownership of all IP for rapid downstream development.